Trials / Completed
CompletedNCT05267054
Treatment of Relapsed or Refractory Diffuse Large B Cell Lymphoma With Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab
A Phase 1b/2 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ociperlimab (BGB-A1217) in Combination With Tislelizumab (BGB-A317) or Rituximab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 53 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to assess the safety and tolerability of ociperlimab (BGB-A1217) in combination with tislelizumab (BGB-A317) or rituximab in participants with relapsed or refractory (R/R) diffuse large B cell lymphoma (DLBCL)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ociperlimab | administered intravenously |
| DRUG | Tislelizumab | Administered intravenously once every 3 weeks |
| DRUG | Rituximab | Administered intravenously once every 3 weeks |
Timeline
- Start date
- 2022-04-25
- Primary completion
- 2024-08-30
- Completion
- 2024-08-30
- First posted
- 2022-03-04
- Last updated
- 2025-09-15
- Results posted
- 2025-09-15
Locations
19 sites across 1 country: China
Source: ClinicalTrials.gov record NCT05267054. Inclusion in this directory is not an endorsement.